Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTOBIA-BM: Utidelone + Etoposide + Bevacizumab for Breast Cancer Brain Metastases
NCT05781633Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jul 2022
- Primary completion
- Jul 2023
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of utidelone in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05781633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05781633.